January 24th 2025
Oral omadacyline or linezolid was equally efficacious to intravenous dosing for acute bacterial skin infections, and associated with less cost and risks.
December 12th 2024
December 11th 2024
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice
View More
In These COVID 19 Times, Can We Reduce Hospitalizations Due to Skin Infections?
January 13th 2022Shortages of health care workers and an increase in COVID-19 cases has put a severe strain on the health care system. Thus, the opportunity to reduce the hospitalizations for other conditions and expand outpatient treatment opportunities should be welcomed.
Read More
Risk of Guillain-Barre Syndrome Higher with Recombinant Zoster Vaccine Shingrix
December 8th 2021A case series observation study found a slightly higher risk of Guillain-Barre syndrome among Medicare beneficiaries within 42 days after receiving the recombinant zoster vaccine Shingrix, but no changes are needed to guidance recommending the vaccine, investigators said.
Read More
FDA Approves Vaccine to Prevent Shingles in Immunocompromised Adults
July 26th 2021This approval of the non-live, recombinant sub-unit adjuvanted vaccine, Shingrix, is for the prevention of shingles in adults aged 18 years and older with increased risk of immunodeficiency or immunosuppression.
Read More
Contact Precautions in Long-Term VA Facilities Don't Cut MRSA Infections, Study Shows
October 25th 2019Although use of gowns and gloves in targeted settings may still be helpful in preventing health care-associated infections, contact precaution policies in VA long-term care facilities had no impact on MRSA acquisition.
Read More
Comparing Effectiveness of Agents for MSSA Bacteremia
August 16th 2019Evidence demonstrates that antimicrobial therapy with an anti-staphylococcal β-lactam antibiotic is the gold standard for treatment of SAB caused by MSSA, but confusion about which agent—particularly cefazolin versus an anti-staphylococcal penicillin—is preferred remains an unanswered question
Read More